Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.
Last Friday, Chevron announced a $33 billion acquisition of Anadarko Petroleum, one of the biggest energy mergers in years. Motley Fool Contributor Matt Dilallo and Industry Focus host Nick Sciple break down the deal, take a look at Kinder Morgan’s most recent earnings report, and preview upcoming earnings from some of their favorite oil companies.
Marijuana stocks OrganiGram and Aphria reported quarterly earnings this week - here's what you should know. Also, Abbott locks horns with DexCom in diabetes and what's next for Bristol-Myers' now that its Celgene acquisition is official.
We're tapping deep into childhood nostalgia on this show -- kids birthday party staple Chuck E. Cheese is planning to go public in 2019 and the details on Disney+ are finally available. One of these developments should have investors happy, the other one... not so much.
In this episode, we look at the bank earnings (so far) and learn about person-to-person payment platform Zelle. In the latest edition of our Between Two Fools interview series, Fool.com contributor Matt Frankel, CFP sits down with Lou Anne Alexander, Group President of Payments for Early Warning, the company behind person-to-person payment platform Zelle. Later, Frankel and Industry Focus: Financials host Jason Moser discuss earnings from JPMorgan Chase (NYSE: JPM), and both tell listeners about the stocks on their radar this week.
Soon-to-be-public Zoom is a Unicorn among Unicorns -- the company grew its top line over 100% last year and it managed to post a profit. We run through the company prospectus and see whether it is worth investing in ahead up its public debut:
4 years ago, Dow and DuPont merged, creating one of the world’s largest industrial conglomerates. From the start, the plan was to break this newly formed company into 3 separate businesses, each more streamlined and nimble than the combined entity. In early April, the first stage of the breakup took place when New Dow began trading. Motley Fool Contributor Lou Whiteman and Industry Focus host Nick Sciple break down each of the newly formed companies and discuss how investors should be viewing them as they come to market.
Here's why a $1 billion deal with Regeneron failed to spark a rally in Alnylam shares. Also, will genetic discovery be our generation's biggest trend? If so, Illumina, bluebird bio, and Invitae could be top stocks to watch.
WWE stock is up over 5X in the last three years, making it one of the better performing stocks on the market. With sports licensing fees surging, the company recently negotiated a new deal that should position the company to thrive over the next several years. Dan “Pretty Boy” Kline and Nick “Hundred Dollar Man” Sciple break down how the company makes money, recent criticism surrounding the company, and the company’s future on this week’s episode.
Stay tuned till the end to hear our Mount Rushmore of the greatest wrestlers of all time, our favorite highlights from Sunday’s Wrestlemania, and more!
Here’s the latest from around the financial sector, and an interview with a Fool.com contributor with a unique perspective on financial crimes. In this episode of Industry Focus: Financials, host Jason Moser sits down with Fool.com contributor Matt Cochrane, who happens to have a unique day job related to the financial sector. Also, regular guest Matt Frankel, CFP discusses why JPMorgan Chase (NYSE: JPM) CEO Jamie Dimon thinks America’s economic growth isn’t nearly as robust as it could be, and answers a listener question about stock buybacks. Finally, as always, Moser and Frankel each reveal what stocks they’re watching right now.
Get more great information on becoming a better investor -- free and straight to your inbox!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Statement and Terms & Conditions.